NICE recommends use of Santen’s IKERVIS in England to treat severe keratitis
IKERVIS is the first and only topical ciclosporin preparation licensed for the treatment of severe keratitis in patients with dry eye disease in the UK. It is estimated
ProBio has entered into an exclusive worldwide licensing agreement with South Korean biotechnology firm AbTis to develop and commercialise an early-stage therapeutic antibody asset.
Both technologies originate from the pioneering work of Don J. Diamond, Ph.D., chair of the Department of Experimental Therapeutics at City of Hope, an independent biomedical research institution